Crinecerfont confers long-term benefits for children with congenital adrenal hyperplasia

Long-term use of crinecerfont reduced glucocorticoid dosage over 2 years and was tied to multiple improvements in clinical outcomes for children and adolescents with classic congenital adrenal hyperplasia, researchers reported. As Healio previously reported, adults with classic CAH had sustained declines in glucocorticoid dose at 2 years with crinecerfont (Crenessity, Neurocrine Biosciences). In